Tag - RARX

Developments

Ra Pharma doses first patient in Phase 2 immune-mediated necrotizing myopathy study

Ra Pharmaceuticals (NASDAQ:RARX) dosed the first patient in its Phase 2 clinical trial evaluating zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). IMNM is an autoimmune disease characterized...

December 5, 2019

Developments

Ra Pharma doses first patient in pivotal Phase 3 myasthenia gravis study

Ra Pharmaceuticals (NASDAQ:RARX) dosed the first patient in its RAISE study, a pivotal Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG). gMG is a chronic autoimmune...

October 2, 2019

Tag - RARX

Ra Pharma doses first patient in Phase 2 immune-mediated necrotizing myopathy study

Ra Pharma doses first patient in pivotal Phase 3 myasthenia gravis study

General

More